Advertisement
ALGN vs IDXX
Which Stock Would AI Choose? Align Technology (ALGN) vs. IDEXX Laboratories (IDXX) Stock Comparison
Key Takeaways
- Tickeron AI Verdict: IDEXX Laboratories (IDXX) is the preferred pick, reflecting a more consistent recurring-revenue model and stronger trend stability versus Align Technology's softer near-term growth.
- ALGN beat earnings estimates but lowered its full-year revenue outlook and announced a CEO transition, weighing on sentiment.
- IDXX continues to grow recurring companion-animal diagnostics revenue at a double-digit pace, even as U.S. veterinary visit trends remain soft.
- The two businesses serve very different end markets: consumer discretionary dental care versus resilient pet healthcare diagnostics.
- For more on each name, explore ALGN Major News and ALGN Today's Price Move, plus IDXX Major News and IDXX Today's Price Move.
- Discover curated AI trading strategies on Tickeron's Trending AI Robots page.
Introduction
Align Technology (ALGN) and IDEXX Laboratories (IDXX) are both healthcare leaders, yet they serve fundamentally different customers. ALGN is best known for its Invisalign clear aligners and iTero intraoral scanners in the discretionary dental market, while IDXX dominates companion-animal veterinary diagnostics with a razor-and-blade model built on recurring consumable revenue. This stock comparison is relevant to investors weighing growth versus stability, as both names have navigated a challenging consumer backdrop in recent weeks. Traders and long-term investors evaluating relative performance, market positioning, and risk tolerance may find the contrast between a cyclical dental franchise and a defensive diagnostics compounder instructive.
ALGN Overview and Recent Performance
Align Technology is a leading medical device company in digital orthodontics and restorative dentistry. Its core Invisalign clear aligner franchise drives most of its revenue, supported by iTero scanners and CAD/CAM (computer-aided design and manufacturing) software. In its most recent quarter, revenue rose roughly 1.9% year over year to about $1.01 billion, with non-GAAP earnings per share slightly ahead of consensus. Clear aligner shipments increased approximately 6.6%, helped by record doctor participation and double-digit international growth in EMEA, APAC, and Latin America.
However, near-term sentiment has been pressured by several factors. Management lowered its full-year revenue outlook, citing a cautious consumer and softness in North American general-practitioner retail demand. Systems and services revenue declined as customers shifted toward lower-priced scanner configurations and flexible acquisition models. The company also announced a CEO transition, adding an element of uncertainty. Analysts have trimmed price targets while remaining split on the outlook, and the stock has traded below its 52-week high in recent market activity.
IDXX Overview and Recent Performance
IDEXX Laboratories is a global leader in pet healthcare innovation, providing point-of-care diagnostic instruments, reference laboratory services, rapid assay tests, and veterinary software. Its Companion Animal Group (CAG) segment is the primary growth engine, characterized by a sticky installed base and recurring consumable revenue. Worldwide CAG diagnostics recurring revenue has grown at a double-digit organic rate, supported by net new customers, higher utilization, and price improvements.
IDXX has also expanded its innovation pipeline, including the inVue Dx platform, Cancer Dx testing, and an acquisition of CoVetAI to strengthen veterinary workflow intelligence. The main headwind has been weakness in U.S. same-store clinical visits, which declined modestly, along with some foreign exchange pressure. Despite this, the stock maintains a premium valuation and a generally constructive "Buy" consensus among analysts, with price targets implying meaningful upside. IDXX's earnings are scheduled for early November, making near-term performance sensitive to its quarterly update.
Trending AI Robots
Tickeron maintains a large library of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and set of symbols. Rather than showcasing every bot, Tickeron curates a focused Trending AI Robots section that highlights the strategies best suited to current market conditions. These bots span various approaches, from swing trading to longer-horizon trend following, giving traders a way to evaluate quantitative signals alongside their own research. Exploring the curated list can help investors see how algorithmic models are positioning across names like ALGN and IDXX and identify strategies aligned with their own objectives and risk tolerance.
Head-to-Head Comparison
ALGN and IDXX diverge sharply across several dimensions. Business model: ALGN is tied to discretionary consumer spending on elective dental treatment, making it more cyclical and sensitive to macroeconomic pressure. IDXX operates a more defensive razor-and-blade model, where instrument placements generate long-term recurring consumable revenue. Growth drivers: ALGN leans on clear aligner volume growth and international expansion, whereas IDXX benefits from rising diagnostic utilization, an expanding test menu, and software attach rates. Momentum: ALGN recently lowered guidance and faces a leadership transition, while IDXX has maintained double-digit recurring-revenue growth despite soft U.S. clinic visits. Risk factors: ALGN faces competition in clear aligners and consumer demand volatility; IDXX contends with valuation risk, foreign exchange exposure, and slower visit growth. Valuation and sentiment: IDXX trades at a notable earnings-multiple premium and carries a broad analyst "Buy" consensus, while ALGN's fair value estimates have been trimmed amid a more cautious, divided view.
Tickeron AI Verdict
Based on observable factors such as trend consistency, revenue stability, catalyst profile, and relative positioning, Tickeron's AI currently favors IDXX. The company's recurring-revenue structure, durable double-digit diagnostic growth, and more constructive analyst consensus suggest a steadier underlying trend than ALGN, which faces softer guidance, a CEO transition, and discretionary-demand headwinds. This assessment is probabilistic and reflects current market conditions rather than a definitive forecast; both stocks carry distinct risk-and-return profiles that investors should weigh against their own objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALGN is a Buy and IDXX is a StrongBuy.
ALGN in upward trend: price rose above 50-day moving average on November 02, 2026
ALGN moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend. In 34 of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ALGN as a result. In 57 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for ALGN just turned positive on October 08, 2026. Looking at past instances where ALGN's MACD turned positive, the stock continued to rise in 31 of 41 cases over the following month. The odds of a continued upward trend are 76%.
The 10-day moving average for ALGN crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +1.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGN advanced for three days, in 190 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 63 cases where ALGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
ALGN broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALGN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. ALGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.768) is normal, around the industry mean (5.069). P/E Ratio (28.579) is within average values for comparable stocks, (40.009). Projected Growth (PEG Ratio) (0.611) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.612) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IDXX in upward trend: 10-day moving average crossed above 50-day moving average on October 21, 2026
The 10-day moving average for IDXX crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on IDXX as a result. In 58 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
IDXX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDXX advanced for three days, in 178 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 97 of 171 cases where IDXX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDXX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
IDXX broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. IDXX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 67 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (34.127) is normal, around the industry mean (66.911). P/E Ratio (48.816) is within average values for comparable stocks, (2.514). Projected Growth (PEG Ratio) (2.894) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (9.042) is also within normal values, averaging (9.775).
ALGN | IDXX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 43 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 86 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 84 | |
SMR RATING 1..100 | 69 | 16 | |
PRICE GROWTH RATING 1..100 | 56 | 38 | |
P/E GROWTH RATING 1..100 | 37 | 67 | |
SEASONALITY SCORE 1..100 | 8 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALGN's Valuation (63) in the Medical Specialties industry is in the same range as IDXX (86). This means that ALGN’s stock grew similarly to IDXX’s over the last 12 months.
IDXX's Profit vs Risk Rating (84) in the Medical Specialties industry is in the same range as ALGN (100). This means that IDXX’s stock grew similarly to ALGN’s over the last 12 months.
IDXX's SMR Rating (16) in the Medical Specialties industry is somewhat better than the same rating for ALGN (69). This means that IDXX’s stock grew somewhat faster than ALGN’s over the last 12 months.
IDXX's Price Growth Rating (38) in the Medical Specialties industry is in the same range as ALGN (56). This means that IDXX’s stock grew similarly to ALGN’s over the last 12 months.
ALGN's P/E Growth Rating (37) in the Medical Specialties industry is in the same range as IDXX (67). This means that ALGN’s stock grew similarly to IDXX’s over the last 12 months.
| ALGN | IDXX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 71% | 1 day ago 64% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 71% |
| Momentum ODDS (%) | 1 day ago 71% | 1 day ago 62% |
| MACD ODDS (%) | 1 day ago 76% | N/A |
| TrendWeek ODDS (%) | 1 day ago 73% | 1 day ago 61% |
| TrendMonth ODDS (%) | 1 day ago 72% | 1 day ago 53% |
| Advances ODDS (%) | 7 days ago 70% | 1 day ago 62% |
| Declines ODDS (%) | 9 days ago 76% | 29 days ago 69% |
| BollingerBands ODDS (%) | 1 day ago 74% | 1 day ago 77% |
| Aroon ODDS (%) | 1 day ago 74% | 1 day ago 57% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALGN’s FA Score shows that 0 FA rating(s) are green while IDXX’s FA Score has 1 green FA rating(s).
- ALGN’s FA Score: 0 green, 5 red.
- IDXX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALGN’s TA Score shows that 5 TA indicator(s) are bullish while IDXX’s TA Score has 5 bullish TA indicator(s).
- ALGN’s TA Score: 5 bullish, 5 bearish.
- IDXX’s TA Score: 5 bullish, 4 bearish.
Price Growth
ALGN (@Pharmaceuticals: Other) experienced а +7.34% price change this week, while IDXX (@Medical Specialties) price change was +24.10% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.75%. For the same industry, the average monthly price growth was +2.25%, and the average quarterly price growth was +16.03%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.74%. For the same industry, the average monthly price growth was -6.91%, and the average quarterly price growth was +44.46%.
Reported Earning Dates
ALGN is expected to report earnings on Feb 03, 2027.
IDXX is expected to report earnings on Feb 08, 2027.
Industries' Descriptions
@Pharmaceuticals: Other (+3.75% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-3.74% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
IDXX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IDXX has been loosely correlated with ALGN. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if IDXX jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To IDXX | 1D Price Change % | ||
|---|---|---|---|---|
| IDXX | 100% | +3.94% | ||
| ALGN - IDXX | 50% Loosely correlated | +8.79% | ||
| SYK - IDXX | 48% Loosely correlated | +9.37% | ||
| BLCO - IDXX | 45% Loosely correlated | +2.85% | ||
| SNN - IDXX | 44% Loosely correlated | +7.59% | ||
| STE - IDXX | 40% Loosely correlated | +7.16% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| EOS.X | 0.083702 | 0.002857 | +3.53% |
| EOS cryptocurrency | |||
| DUSK.X | 0.078971 | 0.002079 | +2.70% |
| Dusk cryptocurrency | |||
| MDT.X | 0.004890 | 0.000079 | +1.65% |
| Measurable Data Token cryptocurrency | |||
| STRK.X | 0.042584 | 0.000202 | +0.48% |
| Starknet cryptocurrency | |||
| AGLD.X | 0.173510 | -0.002481 | -1.41% |
| Adventure Gold cryptocurrency | |||